This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

This study has been terminated.
(Slow accrual.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group Identifier:
First received: October 3, 2003
Last updated: February 12, 2013
Last verified: February 2013
Results First Received: January 7, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Lymphoma
Intervention: Drug: cyclosporine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from ECOG member institutions between September 2, 2005 and March 24, 2009. The study was terminated due to slow accrual.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6) and 150-250 ng/mL during the maintenance period (weeks 7-36) in the absence of renal toxicity.

High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.

Participant Flow for 2 periods

Period 1:   Step 1
Treated   3 
Withdrawal by Subject                1 
Adverse Event                1 

Period 2:   Step 2
STARTED   1 [1] 
Adverse Event                1 
[1] One patient completed step 1, but opted to get alternative therapy. One patient entered step 2.

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Cyclosporine No text entered.

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (42 to 65) 
[Units: Participants]
Female   1 
Male   3 
Region of Enrollment 
[Units: Participants]
United States   4 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Response Rate (Complete and Partial Response)   [ Time Frame: Assessed at weeks 6, 12, 24 and 36 from onset of treatment, and then at 1 year, 18 months, 2 years and 3 years from registration during follow-up. ]

2.  Secondary:   Overall Survival   [ Time Frame: Assessed every 3 months for 2 years, then every 6 months for 1 year. ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Study Statistician
Organization: ECOG Statistical Office
phone: 617-632-3012

Responsible Party: Eastern Cooperative Oncology Group Identifier: NCT00070291     History of Changes
Other Study ID Numbers: CDR0000331864
U10CA021115 ( U.S. NIH Grant/Contract )
E2402 ( Other Identifier: Eastern Cooperative Oncology Group (ECOG) )
Study First Received: October 3, 2003
Results First Received: January 7, 2013
Last Updated: February 12, 2013